Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections

American Journal of Infection Control

Volumn 38, Issue 9, 2010, Pages 740-745

  Lee, Ingi ^a   Morales, Knashawn H ^a   Zaoutis, Theoklis E ^a,b   Fishman, Neil O ^a   Nachamkin, Irving ^a   Lautenbach, Ebbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

bloodstream infections; Candida glabrata; hospital charges; mortality

Indexed keywords

FLUCONAZOLE;

ADULT; AGE; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDIASIS; COMORBIDITY; ECONOMIC ASPECT; FEMALE; HOSPITAL CHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; COHORT STUDIES; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGEMIA; HEALTH CARE COSTS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78049408956     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2010.02.016     Document Type: Article

References (25)

1. J. Morgan, M.I. Meltzer, B.D. Plikaytis, A.N. Sofíair, S. Huie-White, and S. Wilcox Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance Infect Control Hosp Epidemiol 26 2005 540 547
2. O. Gudlaugsson, S. Gillespie, K. Lee, J. Van de Berg, J. Hu, and S. Messer Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
3. T.E. Zaoutis, J. Argon, J. Chu, J.A. Berlin, T.J. Walsh, and C. Feudtner The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis Clin Infect Dis 41 2005 1232 1239
4. C. Viscoli, C. Girmenia, A. Marinus, L. Collette, P. Martino, and B. Vandercam Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) Clin Infect Dis 28 1999 1071 1079
5. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 2006 25 31
6. S.V. Komshian, A.K. Uwaydah, J.D. Sobel, and L.R. Crane Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome Rev Infect Dis 11 1989 379 390
7. M.J. Klevay, E.J. Ernst, J.L. Hollanbaugh, J.G. Miller, M.A. Pfaller, and D.J. Diekema Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection Diagn Microbiol Infect Dis 60 2008 273 277
8. S.Y. Ruan, L.N. Lee, J.S. Jerng, C.J. Yu, and P.R. Hsueh Candida glabrata fungaemia in intensive care units Clin Microbiol Infect 14 2008 136 140
9. S. Blot, K. Vandewoude, E. Hoste, J. Poelaert, and F. Colardyn Outcome in critically ill patients with candidal fungaemia: Candida albicans vs Candida glabrata J Hosp Infect 47 2001 308 313
10. M. Weinberger, L. Leibovici, S. Perez, Z. Samra, I. Ostfeld, and I. Levi Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality J Hosp Infect 61 2005 146 154
11. M. Tumbarello, M. Sanguinetti, E.M. Trecarichi, M. La Sorda, M. Rossi, and E. de Carolis Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome J Antimicrob Chemother 62 2008 1379 1385
12. J.R. McDonald, N.D. Friedman, J.E. Stout, D.J. Sexton, and K.S. Kaye Risk factors for ineffective therapy in patients with bloodstream infection Arch Intern Med 165 2005 308 313
13. D. Larone Medically important fungi: a guide to identification 4th ed. 2002 ASM Press Washington, DC
14. National Committe for Clinical Laboratory Standards Methods for antifungal disk diffusion susceptibility testing of yeasts: approved guideline, M44-A 2004 National Committe for Clinical Laboratory Standards Wayne, PA
15. I. Lee, N.O. Fishman, T.E. Zaoutis, K.H. Morales, M.G. Weiner, and M. Synnestvedt Risk factors for fluconazole-resistant Candida glabrata bloodstream infections Arch Intern Med 169 2009 379 383
16. H. MacAdam, T.E. Zaoutis, L.B. Gasink, W.B. Bilker, and E. Lautenbach Investigating the association between antibiotic use and antibiotic resistance Int J Antimicrob Agents 28 2006 325 332
17. P.G. Pappas, J.H. Rex, J.D. Sobel, S.G. Filler, W.E. Dismukes, and T.J. Walsh Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
18. R.M. Mickey, and S. Greenland The impact of confounder selection criteria on effect estimation Am J Epidemiol 129 1989 125 137 (Pubitemid 19030705)
19. S.Y. Ruan, Y.T. Huang, C.C. Chu, C.J. Yu, and P.R. Hsueh Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes Int J Antimicrob Agents 34 2009 236 239
20. A. Malani, J. Hmoud, L. Chiu, P.L. Carver, A. Bielaczyc, and C.A. Kauffman Candida glabrata fungemia: experience in a tertiary care center Clin Infect Dis 41 2005 975 981
21. F. Han, S. Pu, F. Wang, J. Meng, and B. Ge Fitness cost of macrolide resistance in Campylobacter jejuni Int J Antimicrob Agents 34 2009 462 466
22. M.L. Foucault, P. Courvalin, and C. Grillot-Courvalin Fitness cost of VanA-type vancomycin resitsance in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 2354 2359
23. J.B. Anderson Evolution of antifungal-drug resistance: mechanisms and pathogen fitness Nat Rev Microbiol 3 2005 547 556
24. B.D. Alexander, T.C. Byrne, K.L. Smith, K.E. Hanson, K.J. Anstrom, and J.R. Perfect Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents J Clin Microbiol 45 2007 698 706
25. M.A. Pfaller, A. Espinel-Ingroff, and R.N. Jones Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole J Clin Microbiol 42 2004 4577 4580